Clinical Trial Update: Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of MGCD0103 (mocetinostat) given three times weekly in patients with advanced solid tumors or Non-Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• MGCD0103 (mocetinostat) (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Tumors, Non Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED